Have a feature idea you'd love to see implemented?
Let us know!
MXCT MaxCyte Inc
Price (delayed)
$3.45
Market cap
$363.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.34
Enterprise value
$345.28M
MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to
Highlights
The revenue rose by 20% year-on-year
The EPS has grown by 8% YoY
The company's gross profit rose by 18% YoY but it fell by 2.4% QoQ
MXCT's quick ratio is down by 32% since the previous quarter and by 25% year-on-year
MXCT's debt is up by 14% YoY
Key stats
What are the main financial stats of MXCT
Market
Valuations
Earnings
Shares outstanding
105.48M
Market cap
$363.91M
Enterprise value
$345.28M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.7
Price to sales (P/S)
7.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.57
Revenue
$45.6M
EBIT
-$35.74M
EBITDA
-$30.63M
Free cash flow
-$21.23M
Per share
Balance sheet
Liquidity
EPS
-$0.34
Free cash flow per share
-$0.2
Book value per share
$2.03
Revenue per share
$0.43
TBVPS
$2.37
Total assets
$248.61M
Total liabilities
$35.31M
Debt
$18.32M
Equity
$213.3M
Working capital
$155.29M
Debt to equity
0.09
Current ratio
9.81
Quick ratio
8.99
Net debt/EBITDA
0.61
Margins
Efficiency
Dividend
EBITDA margin
-67.2%
Gross margin
86%
Net margin
-78.4%
Operating margin
-101.7%
Return on assets
-13.9%
Return on equity
-16%
Return on invested capital
-16%
Return on capital employed
-15.5%
Return on sales
-78.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MXCT stock price
How has the MaxCyte stock price performed over time
Intraday
-1.15%
1 week
0.29%
1 month
-8.24%
1 year
-20.32%
YTD
-26.6%
QTD
-11.31%
Financial performance
How have MaxCyte's revenue and profit performed over time
Revenue
$45.6M
Gross profit
$39.21M
Operating income
-$46.39M
Net income
-$35.74M
Gross margin
86%
Net margin
-78.4%
The revenue rose by 20% year-on-year
MXCT's net margin is up by 20% YoY
MXCT's operating margin is up by 18% YoY
The company's gross profit rose by 18% YoY but it fell by 2.4% QoQ
Growth
What is MaxCyte's growth rate over time
Valuation
What is MaxCyte stock price valuation
P/E
N/A
P/B
1.7
P/S
7.95
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.57
The EPS has grown by 8% YoY
MXCT's P/B is 15% below its last 4 quarters average of 2.0
The equity has contracted by 9% YoY and by 3.6% from the previous quarter
The revenue rose by 20% year-on-year
MXCT's price to sales (P/S) is 20% less than its last 4 quarters average of 9.9
Efficiency
How efficient is MaxCyte business performance
The ROS has grown by 20% YoY
The return on equity has declined by 4.6% year-on-year and by 3.2% since the previous quarter
The ROA has contracted by 3% YoY and by 2.2% from the previous quarter
Dividends
What is MXCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MXCT.
Financial health
How did MaxCyte financials performed over time
MXCT's quick ratio is down by 32% since the previous quarter and by 25% year-on-year
The current ratio has declined by 31% since the previous quarter and by 24% year-on-year
MXCT's debt is 91% less than its equity
MaxCyte's debt to equity has increased by 29% YoY and by 13% from the previous quarter
MXCT's debt is up by 14% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.